Clinical Study of Entecavir in Treatment of Lamivudine-resistant Chronic Hepatitis B

CAO Meng; LI Wei; HUANG Hao

doi:10.3969/j.issn.1002-3429.2017.09.029

Abstract：Objective To observe clinical effects of Entecavir in treatment of Lamivudine-resistant chronic hepatitis B (CHB).Methods A total of 200 patients with Lamivudine-resistant CHB admitted during February 2010 and March 2012 were treated with 1.0 mg/d Entecavir orally for 4 years.Clinical efficacy, negative rate of hepatitis B virus-deoxyribonucleic acid (HBV-DNA), rebound rate of virology, seroconversion rates of hepatitis B virus e antigen (HBeAg) and hepatitis B virus S antigen (HBsAg) and incidence rate of adverse reactions were observed.Results The total effective rate was 88.0％ in the 24th weeks of treatment, and the total effective rates were stable in the 48th, 96th, 144th and 200th weeks of treatments until the end of treatment.HBV-DNA negative rate was 9.0％ in the 8th week of treatment, and then the rate was gradually increased to 46.0％ in the 96th weeks of treatment, and the rate was 60.0％ in the 200th weeks of treatment.In the 8th week of treatment, 10 patients had virology rebound, and 56 patients had virology rebound at the end of treatment.In the 8th week of treatment, 2 patients had HBeAg seroconversion, and 64 patients had HBeAg seroconversion in the 200th weeks of treatment.In the 144th weeks of treatment, 14 patients had HBsAg seroconversion, and 24 patients had HBsAg seroconversion in the 200th weeks of treatment.Adverse reactions were found in 46 patients (23.0％), who included 18 patients with nausea, 14 patients with fatigue, 10 patients with tachycardia and 4 patients with positive white blood cell in urine, and symptoms were relieved after symptomatic treatment.Conclusion Entecavir in treatment of Lamivudine-resistant chronic hepatitis B can achieve good effect and safety.